Paris, October 10, 2025 — Leads & Copy — AB Science SA (Euronext – FR0010557264 – AB) has released its financial results for the first half of 2025, reporting an operating deficit reduced by 24% to €2.7 million as of June 30, 2025, compared to the first half of 2024. The company also completed a capital increase through private placements totaling €6.3 million.
Clinical development highlights include authorizations from several European countries and the FDA and EMA for Phase 3 studies of masitinib in amyotrophic lateral sclerosis and metastatic hormone-resistant prostate cancer, respectively. New data also demonstrated the efficacy of masitinib in Alzheimer’s disease, and a U.S. patent was granted covering masitinib until 2040 for the treatment of sickle cell disease.
The company also reported regulatory approval in European countries to initiate the third stage of Phase I/II trials combining its AB8939 molecule with Venetoclax in the treatment of acute myeloid leukemia. The EMA granted orphan drug designation for AB8939 in the treatment of AML, and a Canadian patent was granted protecting the composition of AB8939 until 2036.
AB Science also reached an agreement in principle on a two-year deferral of repayment of state-guaranteed loans and received a partial payment of the 2023 Research Tax Credit for €2.934 million.
Financial Communications
investors@ab-science.com
Source: AB Science
